| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tryptophan | 5 | 2021 | 73 | 2.470 |
Why?
|
| Cyclooxygenase 2 | 8 | 2021 | 104 | 1.190 |
Why?
|
| Lung Neoplasms | 5 | 2019 | 358 | 1.180 |
Why?
|
| Fibroblasts | 5 | 2021 | 272 | 1.180 |
Why?
|
| Neoplasm Metastasis | 3 | 2021 | 219 | 0.960 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 4 | 2005 | 41 | 0.940 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2018 | 259 | 0.910 |
Why?
|
| NF-kappa B | 6 | 2018 | 339 | 0.880 |
Why?
|
| Nitric Oxide Synthase | 4 | 2003 | 128 | 0.860 |
Why?
|
| Drug Design | 1 | 2023 | 162 | 0.820 |
Why?
|
| Serotonin | 2 | 2021 | 123 | 0.790 |
Why?
|
| MAP Kinase Signaling System | 2 | 2012 | 169 | 0.760 |
Why?
|
| Gene Expression Regulation, Enzymologic | 4 | 2006 | 168 | 0.750 |
Why?
|
| Acetylserotonin O-Methyltransferase | 2 | 2018 | 4 | 0.750 |
Why?
|
| Proteins | 1 | 2023 | 369 | 0.740 |
Why?
|
| Apoptosis | 7 | 2021 | 1398 | 0.720 |
Why?
|
| Glucose | 3 | 2018 | 230 | 0.700 |
Why?
|
| Enzyme Inhibitors | 3 | 2018 | 433 | 0.690 |
Why?
|
| Cell Proliferation | 9 | 2021 | 1198 | 0.690 |
Why?
|
| Curcumin | 1 | 2018 | 74 | 0.600 |
Why?
|
| Antineoplastic Agents | 3 | 2021 | 803 | 0.520 |
Why?
|
| Mitochondria | 3 | 2009 | 487 | 0.510 |
Why?
|
| Animals | 23 | 2021 | 15081 | 0.500 |
Why?
|
| Mice | 13 | 2021 | 5913 | 0.500 |
Why?
|
| Coronary Disease | 2 | 2008 | 124 | 0.490 |
Why?
|
| Mesenchymal Stem Cells | 5 | 2016 | 62 | 0.490 |
Why?
|
| Nitric Oxide Synthase Type II | 5 | 2006 | 115 | 0.490 |
Why?
|
| CCAAT-Enhancer-Binding Protein-beta | 2 | 2005 | 9 | 0.490 |
Why?
|
| Aspirin | 2 | 2005 | 49 | 0.470 |
Why?
|
| Cell Movement | 6 | 2021 | 571 | 0.460 |
Why?
|
| Breast Neoplasms | 3 | 2021 | 1502 | 0.450 |
Why?
|
| Inflammation | 3 | 2016 | 618 | 0.430 |
Why?
|
| Galectin 3 | 1 | 2012 | 26 | 0.430 |
Why?
|
| Isoenzymes | 2 | 2003 | 161 | 0.420 |
Why?
|
| Mice, SCID | 4 | 2018 | 150 | 0.420 |
Why?
|
| Trans-Activators | 2 | 2003 | 174 | 0.420 |
Why?
|
| 14-3-3 Proteins | 2 | 2012 | 22 | 0.400 |
Why?
|
| Nuclear Proteins | 2 | 2003 | 307 | 0.380 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2012 | 172 | 0.380 |
Why?
|
| Neoplasms | 1 | 2021 | 1103 | 0.380 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2009 | 152 | 0.380 |
Why?
|
| Colonic Neoplasms | 1 | 2012 | 186 | 0.370 |
Why?
|
| Humans | 25 | 2021 | 37093 | 0.350 |
Why?
|
| Macrophages | 2 | 2019 | 439 | 0.350 |
Why?
|
| Acetylation | 4 | 2018 | 98 | 0.340 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2009 | 84 | 0.330 |
Why?
|
| PPAR gamma | 1 | 2009 | 53 | 0.330 |
Why?
|
| Reperfusion Injury | 1 | 2009 | 57 | 0.330 |
Why?
|
| Thiazolidinediones | 1 | 2009 | 50 | 0.330 |
Why?
|
| Colorectal Neoplasms | 2 | 2021 | 441 | 0.330 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 2 | 2007 | 121 | 0.320 |
Why?
|
| Blood Coagulation Factors | 1 | 2008 | 6 | 0.320 |
Why?
|
| Interferon-gamma | 4 | 2013 | 250 | 0.310 |
Why?
|
| Cyclooxygenase 2 Inhibitors | 4 | 2012 | 25 | 0.300 |
Why?
|
| Cell Line | 3 | 2021 | 1354 | 0.300 |
Why?
|
| Up-Regulation | 3 | 2009 | 513 | 0.300 |
Why?
|
| Cyclooxygenase Inhibitors | 2 | 2005 | 30 | 0.290 |
Why?
|
| Cell Line, Tumor | 5 | 2019 | 2231 | 0.290 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 3 | 2016 | 9 | 0.280 |
Why?
|
| NF-kappa B p52 Subunit | 1 | 2006 | 5 | 0.280 |
Why?
|
| Tumor Cells, Cultured | 3 | 2018 | 502 | 0.280 |
Why?
|
| Platelet Activation | 1 | 2005 | 4 | 0.260 |
Why?
|
| Myocardial Infarction | 2 | 2021 | 225 | 0.260 |
Why?
|
| Blood Coagulation | 1 | 2005 | 23 | 0.260 |
Why?
|
| Phospholipases A | 1 | 2005 | 10 | 0.260 |
Why?
|
| Melatonin | 1 | 2006 | 82 | 0.260 |
Why?
|
| Plant Preparations | 1 | 2005 | 27 | 0.260 |
Why?
|
| Salicylates | 1 | 2005 | 9 | 0.260 |
Why?
|
| Evidence-Based Medicine | 1 | 2005 | 97 | 0.250 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2005 | 22 | 0.250 |
Why?
|
| Receptors, G-Protein-Coupled | 2 | 2019 | 86 | 0.250 |
Why?
|
| Liver Neoplasms | 2 | 2021 | 190 | 0.250 |
Why?
|
| Tryptophan Hydroxylase | 2 | 2016 | 5 | 0.250 |
Why?
|
| Thrombosis | 1 | 2005 | 63 | 0.250 |
Why?
|
| Phosphorylation | 4 | 2018 | 928 | 0.250 |
Why?
|
| Acetyltransferases | 1 | 2003 | 27 | 0.240 |
Why?
|
| Promoter Regions, Genetic | 5 | 2012 | 515 | 0.230 |
Why?
|
| Ligands | 2 | 2023 | 349 | 0.230 |
Why?
|
| RNA Interference | 3 | 2016 | 243 | 0.230 |
Why?
|
| Salicylic Acid | 1 | 2003 | 7 | 0.230 |
Why?
|
| Thrombomodulin | 1 | 2003 | 5 | 0.230 |
Why?
|
| Calmodulin | 1 | 2003 | 46 | 0.230 |
Why?
|
| Models, Biological | 2 | 2012 | 677 | 0.220 |
Why?
|
| Intercellular Adhesion Molecule-1 | 1 | 2003 | 56 | 0.220 |
Why?
|
| Molecular Structure | 2 | 2023 | 492 | 0.220 |
Why?
|
| Arginine | 1 | 2003 | 73 | 0.210 |
Why?
|
| Tyrosine | 1 | 2003 | 118 | 0.210 |
Why?
|
| Protein Binding | 5 | 2012 | 972 | 0.210 |
Why?
|
| Arteriosclerosis | 2 | 2013 | 36 | 0.210 |
Why?
|
| Interleukin-10 | 2 | 2013 | 75 | 0.210 |
Why?
|
| Cytochromes c | 3 | 2009 | 53 | 0.210 |
Why?
|
| Oxidative Stress | 2 | 2021 | 938 | 0.190 |
Why?
|
| Reactive Oxygen Species | 3 | 2021 | 461 | 0.190 |
Why?
|
| Matrix Metalloproteinases | 1 | 2021 | 48 | 0.190 |
Why?
|
| Immunity | 1 | 2021 | 53 | 0.190 |
Why?
|
| RNA, Small Interfering | 3 | 2012 | 409 | 0.190 |
Why?
|
| Calcium | 1 | 2003 | 480 | 0.180 |
Why?
|
| Hydrogen Peroxide | 3 | 2021 | 190 | 0.180 |
Why?
|
| HT29 Cells | 3 | 2019 | 45 | 0.180 |
Why?
|
| Disease Models, Animal | 4 | 2021 | 1371 | 0.180 |
Why?
|
| Membrane Proteins | 4 | 2005 | 517 | 0.180 |
Why?
|
| Succinic Acid | 1 | 2019 | 1 | 0.180 |
Why?
|
| Transfection | 4 | 2012 | 523 | 0.180 |
Why?
|
| Autophagy | 1 | 2021 | 116 | 0.180 |
Why?
|
| Immunomodulation | 2 | 2016 | 15 | 0.170 |
Why?
|
| Pancreatic Neoplasms | 1 | 2021 | 111 | 0.170 |
Why?
|
| Fatty Acids, Nonesterified | 2 | 2017 | 42 | 0.170 |
Why?
|
| bcl-Associated Death Protein | 2 | 2009 | 9 | 0.160 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2016 | 95 | 0.160 |
Why?
|
| Ventricular Function, Left | 2 | 2021 | 96 | 0.160 |
Why?
|
| Coculture Techniques | 2 | 2016 | 101 | 0.160 |
Why?
|
| Hyperglycemia | 1 | 2018 | 55 | 0.150 |
Why?
|
| Female | 8 | 2021 | 20969 | 0.150 |
Why?
|
| Smad4 Protein | 1 | 2017 | 7 | 0.150 |
Why?
|
| Immune System Diseases | 1 | 2016 | 21 | 0.140 |
Why?
|
| Sulindac | 2 | 2007 | 9 | 0.140 |
Why?
|
| Pluripotent Stem Cells | 1 | 2016 | 32 | 0.140 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2017 | 52 | 0.140 |
Why?
|
| Femoral Artery | 2 | 2013 | 12 | 0.140 |
Why?
|
| Vimentin | 1 | 2016 | 37 | 0.140 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 213 | 0.140 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2012 | 1039 | 0.140 |
Why?
|
| Cytoskeleton | 1 | 2016 | 110 | 0.130 |
Why?
|
| Cells, Cultured | 4 | 2012 | 1518 | 0.130 |
Why?
|
| Cadherins | 1 | 2016 | 90 | 0.130 |
Why?
|
| Disease Progression | 1 | 2018 | 601 | 0.130 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 2 | 2013 | 7 | 0.130 |
Why?
|
| Pyrazoles | 2 | 2007 | 85 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 2 | 2012 | 103 | 0.130 |
Why?
|
| Sulfonamides | 2 | 2007 | 80 | 0.130 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2016 | 93 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 1 | 2017 | 197 | 0.130 |
Why?
|
| E1A-Associated p300 Protein | 2 | 2006 | 11 | 0.130 |
Why?
|
| Embryonic Stem Cells | 2 | 2012 | 59 | 0.130 |
Why?
|
| Models, Molecular | 1 | 2018 | 808 | 0.120 |
Why?
|
| Male | 7 | 2018 | 20025 | 0.120 |
Why?
|
| Receptors, CXCR4 | 1 | 2014 | 69 | 0.120 |
Why?
|
| NADP | 2 | 2003 | 38 | 0.110 |
Why?
|
| NF-kappa B p50 Subunit | 2 | 2003 | 15 | 0.110 |
Why?
|
| Lipopolysaccharides | 2 | 2006 | 220 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type III | 2 | 2003 | 67 | 0.110 |
Why?
|
| Acetophenones | 1 | 2012 | 10 | 0.110 |
Why?
|
| Protein Kinase C-delta | 1 | 2012 | 18 | 0.110 |
Why?
|
| Benzopyrans | 1 | 2012 | 14 | 0.110 |
Why?
|
| raf Kinases | 1 | 2012 | 7 | 0.110 |
Why?
|
| Dinoprostone | 1 | 2013 | 63 | 0.110 |
Why?
|
| Cell Survival | 3 | 2012 | 864 | 0.110 |
Why?
|
| Catalysis | 2 | 2003 | 179 | 0.110 |
Why?
|
| Caco-2 Cells | 1 | 2012 | 52 | 0.110 |
Why?
|
| Cell Differentiation | 2 | 2016 | 587 | 0.110 |
Why?
|
| Transplantation, Heterologous | 1 | 2012 | 90 | 0.110 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2013 | 59 | 0.110 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2012 | 27 | 0.110 |
Why?
|
| Biocatalysis | 1 | 2012 | 28 | 0.110 |
Why?
|
| Neoplasm Transplantation | 1 | 2012 | 122 | 0.110 |
Why?
|
| Morpholines | 1 | 2012 | 69 | 0.110 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2012 | 54 | 0.110 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2012 | 32 | 0.110 |
Why?
|
| Chemotaxis | 1 | 2012 | 60 | 0.110 |
Why?
|
| Subcellular Fractions | 1 | 2012 | 77 | 0.110 |
Why?
|
| ras Proteins | 1 | 2012 | 51 | 0.100 |
Why?
|
| Chromones | 1 | 2012 | 54 | 0.100 |
Why?
|
| Solubility | 1 | 2012 | 118 | 0.100 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 48 | 0.100 |
Why?
|
| Metabolic Networks and Pathways | 1 | 2012 | 67 | 0.100 |
Why?
|
| Flavonoids | 1 | 2012 | 87 | 0.100 |
Why?
|
| beta Catenin | 1 | 2012 | 48 | 0.100 |
Why?
|
| Enzyme Activation | 2 | 2003 | 444 | 0.100 |
Why?
|
| Gene Knockdown Techniques | 1 | 2012 | 173 | 0.100 |
Why?
|
| Metabolomics | 1 | 2012 | 81 | 0.100 |
Why?
|
| Heme Oxygenase-1 | 1 | 2011 | 51 | 0.100 |
Why?
|
| Interleukin-6 | 1 | 2012 | 153 | 0.100 |
Why?
|
| Induced Pluripotent Stem Cells | 1 | 2011 | 37 | 0.100 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2012 | 86 | 0.100 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2012 | 130 | 0.100 |
Why?
|
| Atherosclerosis | 1 | 2012 | 134 | 0.100 |
Why?
|
| Neoplasm Proteins | 1 | 2012 | 213 | 0.090 |
Why?
|
| Cyclohexanecarboxylic Acids | 1 | 2010 | 5 | 0.090 |
Why?
|
| Amino Acid Sequence | 2 | 2003 | 1180 | 0.090 |
Why?
|
| Cyclohexenes | 1 | 2010 | 4 | 0.090 |
Why?
|
| Carboxylic Acids | 1 | 2010 | 13 | 0.090 |
Why?
|
| Oxadiazoles | 1 | 2010 | 15 | 0.090 |
Why?
|
| Molecular Sequence Data | 2 | 2003 | 1568 | 0.090 |
Why?
|
| Transcription, Genetic | 1 | 2012 | 578 | 0.090 |
Why?
|
| Caspase 9 | 1 | 2009 | 30 | 0.090 |
Why?
|
| bcl-X Protein | 1 | 2009 | 27 | 0.090 |
Why?
|
| Anilides | 1 | 2009 | 28 | 0.090 |
Why?
|
| Cytoprotection | 1 | 2009 | 36 | 0.090 |
Why?
|
| Cell Hypoxia | 1 | 2009 | 58 | 0.090 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2010 | 112 | 0.090 |
Why?
|
| Poly(ADP-ribose) Polymerases | 1 | 2009 | 78 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2010 | 82 | 0.080 |
Why?
|
| Mice, Inbred C57BL | 4 | 2019 | 1609 | 0.080 |
Why?
|
| Signal Transduction | 4 | 2021 | 1908 | 0.080 |
Why?
|
| Binding, Competitive | 2 | 2010 | 111 | 0.080 |
Why?
|
| Caspase 3 | 1 | 2009 | 207 | 0.080 |
Why?
|
| Time Factors | 2 | 2012 | 1742 | 0.080 |
Why?
|
| Neuroblastoma | 1 | 2009 | 129 | 0.080 |
Why?
|
| Swine | 3 | 2014 | 184 | 0.080 |
Why?
|
| Protein Transport | 2 | 2012 | 302 | 0.080 |
Why?
|
| PPAR delta | 1 | 2007 | 3 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2009 | 269 | 0.070 |
Why?
|
| Indomethacin | 1 | 2007 | 28 | 0.070 |
Why?
|
| Adenoviridae | 1 | 2007 | 62 | 0.070 |
Why?
|
| Cell Nucleus | 2 | 2012 | 366 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2012 | 807 | 0.070 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2006 | 2 | 0.070 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2006 | 10 | 0.070 |
Why?
|
| Peptide Hormones | 1 | 2006 | 20 | 0.070 |
Why?
|
| Intestine, Small | 1 | 2006 | 25 | 0.070 |
Why?
|
| Cholecystokinin | 1 | 2006 | 16 | 0.070 |
Why?
|
| Fibrinolytic Agents | 1 | 2005 | 25 | 0.070 |
Why?
|
| Group VI Phospholipases A2 | 1 | 2005 | 2 | 0.060 |
Why?
|
| Phospholipases A2 | 1 | 2005 | 9 | 0.060 |
Why?
|
| Arachidonic Acid | 1 | 2005 | 35 | 0.060 |
Why?
|
| Chaperonin 60 | 1 | 2005 | 18 | 0.060 |
Why?
|
| Risk Assessment | 1 | 2008 | 753 | 0.060 |
Why?
|
| Microscopy, Confocal | 1 | 2005 | 218 | 0.060 |
Why?
|
| Mice, Knockout | 3 | 2012 | 933 | 0.060 |
Why?
|
| Mitochondrial Proteins | 1 | 2005 | 107 | 0.060 |
Why?
|
| Ferricyanides | 1 | 2003 | 2 | 0.060 |
Why?
|
| Histone Acetyltransferases | 1 | 2003 | 19 | 0.060 |
Why?
|
| Citrulline | 1 | 2003 | 10 | 0.060 |
Why?
|
| Baculoviridae | 1 | 2003 | 14 | 0.060 |
Why?
|
| Cohort Studies | 1 | 2008 | 1492 | 0.060 |
Why?
|
| Nitrites | 1 | 2003 | 46 | 0.060 |
Why?
|
| Sequence Deletion | 1 | 2003 | 87 | 0.060 |
Why?
|
| Flow Cytometry | 1 | 2005 | 399 | 0.060 |
Why?
|
| Nitrates | 1 | 2003 | 40 | 0.060 |
Why?
|
| Culture Media | 1 | 2003 | 90 | 0.060 |
Why?
|
| Chelating Agents | 1 | 2003 | 57 | 0.060 |
Why?
|
| Hydroxylation | 1 | 2003 | 15 | 0.060 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 201 | 0.060 |
Why?
|
| DNA, Complementary | 1 | 2003 | 191 | 0.060 |
Why?
|
| Chromatography, Gel | 1 | 2003 | 50 | 0.060 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2003 | 269 | 0.060 |
Why?
|
| Middle Aged | 3 | 2008 | 10129 | 0.060 |
Why?
|
| Gene Deletion | 1 | 2003 | 166 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2003 | 56 | 0.050 |
Why?
|
| Amino Acid Substitution | 1 | 2003 | 132 | 0.050 |
Why?
|
| Transplantation, Homologous | 2 | 2013 | 36 | 0.050 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 172 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2003 | 188 | 0.050 |
Why?
|
| Protein Structure, Tertiary | 1 | 2003 | 408 | 0.050 |
Why?
|
| Oxygen | 1 | 2003 | 207 | 0.050 |
Why?
|
| DNA Primers | 1 | 2003 | 286 | 0.050 |
Why?
|
| Proportional Hazards Models | 1 | 2003 | 441 | 0.050 |
Why?
|
| Oxidation-Reduction | 1 | 2003 | 431 | 0.050 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 515 | 0.050 |
Why?
|
| Myocarditis | 1 | 2021 | 20 | 0.050 |
Why?
|
| Kinetics | 1 | 2003 | 708 | 0.050 |
Why?
|
| Cell Line, Transformed | 1 | 2021 | 91 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2003 | 316 | 0.050 |
Why?
|
| Base Sequence | 1 | 2003 | 997 | 0.050 |
Why?
|
| Ventricular Remodeling | 1 | 2021 | 57 | 0.050 |
Why?
|
| Biological Assay | 1 | 2021 | 59 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 356 | 0.050 |
Why?
|
| Lysosomes | 1 | 2021 | 91 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2003 | 1130 | 0.040 |
Why?
|
| Myocytes, Cardiac | 1 | 2021 | 166 | 0.040 |
Why?
|
| Myocardium | 1 | 2021 | 235 | 0.040 |
Why?
|
| Rats | 2 | 2021 | 3483 | 0.040 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2019 | 84 | 0.040 |
Why?
|
| Mutation | 1 | 2003 | 1095 | 0.040 |
Why?
|
| United States | 1 | 2008 | 4223 | 0.040 |
Why?
|
| Treatment Outcome | 1 | 2021 | 1369 | 0.040 |
Why?
|
| Ubiquitination | 1 | 2017 | 61 | 0.040 |
Why?
|
| rho-Associated Kinases | 1 | 2016 | 31 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2021 | 1618 | 0.030 |
Why?
|
| Mice, Nude | 1 | 2017 | 337 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2016 | 90 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2016 | 204 | 0.030 |
Why?
|
| Risk Factors | 1 | 2003 | 3562 | 0.030 |
Why?
|
| Porcine Reproductive and Respiratory Syndrome | 1 | 2014 | 1 | 0.030 |
Why?
|
| Stress Fibers | 1 | 2012 | 4 | 0.030 |
Why?
|
| Lipopeptides | 1 | 2012 | 21 | 0.030 |
Why?
|
| Immune Tolerance | 1 | 2013 | 65 | 0.030 |
Why?
|
| Wnt Proteins | 1 | 2012 | 22 | 0.030 |
Why?
|
| rac GTP-Binding Proteins | 1 | 2012 | 22 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2012 | 8 | 0.030 |
Why?
|
| Protein Stability | 1 | 2012 | 45 | 0.030 |
Why?
|
| Neuropeptides | 1 | 2012 | 59 | 0.030 |
Why?
|
| rac1 GTP-Binding Protein | 1 | 2012 | 46 | 0.030 |
Why?
|
| Octamer Transcription Factor-3 | 1 | 2011 | 19 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2012 | 99 | 0.030 |
Why?
|
| Teratoma | 1 | 2011 | 9 | 0.030 |
Why?
|
| Multiprotein Complexes | 1 | 2012 | 54 | 0.030 |
Why?
|
| Genetic Complementation Test | 1 | 2011 | 59 | 0.030 |
Why?
|
| Neoplasms, Experimental | 1 | 2011 | 37 | 0.030 |
Why?
|
| Graft Survival | 1 | 2012 | 39 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2012 | 122 | 0.030 |
Why?
|
| Antibodies, Neutralizing | 1 | 2012 | 109 | 0.030 |
Why?
|
| Alkaline Phosphatase | 1 | 2011 | 50 | 0.030 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 81 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2012 | 112 | 0.030 |
Why?
|
| Genetic Vectors | 1 | 2012 | 158 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 76 | 0.020 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2011 | 93 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 1 | 2010 | 25 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2010 | 88 | 0.020 |
Why?
|
| Cricetulus | 1 | 2010 | 80 | 0.020 |
Why?
|
| CHO Cells | 1 | 2010 | 124 | 0.020 |
Why?
|
| Vasodilation | 1 | 2010 | 65 | 0.020 |
Why?
|
| Cricetinae | 1 | 2010 | 238 | 0.020 |
Why?
|
| Dogs | 1 | 2010 | 149 | 0.020 |
Why?
|
| Gene Expression | 1 | 2013 | 674 | 0.020 |
Why?
|
| Receptors, Nicotinic | 1 | 2010 | 106 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2010 | 207 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2010 | 409 | 0.020 |
Why?
|
| Obesity | 1 | 2017 | 1067 | 0.020 |
Why?
|
| Intubation, Gastrointestinal | 1 | 2006 | 5 | 0.020 |
Why?
|
| Pyloric Antrum | 1 | 2006 | 6 | 0.020 |
Why?
|
| Pylorus | 1 | 2006 | 5 | 0.020 |
Why?
|
| Intestinal Absorption | 1 | 2006 | 20 | 0.020 |
Why?
|
| Ghrelin | 1 | 2006 | 13 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2006 | 55 | 0.020 |
Why?
|
| Pressure | 1 | 2006 | 43 | 0.020 |
Why?
|
| Insulin | 1 | 2006 | 236 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2006 | 353 | 0.010 |
Why?
|
| Adolescent | 1 | 2006 | 5363 | 0.010 |
Why?
|
| Adult | 1 | 2006 | 11712 | 0.010 |
Why?
|